We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. Quince Therapeutics, Inc. (NASDAQ:QNCX) is among the most popular penny stocks.
TheFly reported that QNCX presented Phase 2a clinical results for LAM-001 on May 18, at the American Thoracic Society conference in Orlando, evaluating an inhaled rapamycin formulation for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The drug was studied as an add-on to standard therapy in a 24-week, open-label trial across four sites involving 10 symptomatic adult patients. Outcomes assessed included exercise capacity, pulmonary hemodynamics, cardiac biomarkers, and safety measures.
Results showed improvements or stabilization across multiple disease indicators such as six-minute walk distance, pulmonary vascular resistance, NT-proBNP levels, and lung function metrics. Most patients improved functional class status over the study period, and the treatment was generally well tolerated alongside background therapies, including treprostinil in PH-ILD patients.
Simultaneously, on the same day, Quince Therapeutics, Inc. (NASDAQ:QNCX) announced the completion of its acquisition of Orphai Therapeutics Inc. on May 18, 2026, integrating Orphai’s lead candidate LAM-001 into its pipeline for rare pulmonary diseases. LAM-001, an inhaled rapamycin formulation, has recently shown Phase 2 clinical results in pulmonary arterial hypertension and PH-ILD. Alongside the acquisition, the company entered a financing arrangement expected to raise to $187 million in gross proceeds, including initial and potential additional warrant-based funding.
The capital is intended to support the advancement of LAM-001 through multiple upcoming clinical milestones across pulmonary indications, including PH-ILD, BOS, and sarcoidosis-associated pulmonary hypertension. Management highlighted that the transaction strengthens both the company’s pipeline and financial position.
Quince Therapeutics, Inc. (NASDAQ:QNCX) is a biotech company developing rare disease therapies using patients’ own biology. In May 2026, it expanded its pipeline by acquiring Orphai Therapeutics, adding programs in rare pulmonary and cardiovascular diseases.
While we acknowledge the risk and potential of QNCX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than QNCX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 12 Best Strong Buy Tech Stocks to Invest In Now and 10 Most Widely Held Stocks by Individuals in 2026 .
Disclosure: None. Follow Insider Monkey on Google News.
